Coronary Angioplasty

Antibody Improves Long-Term Outcome

Published in Blood Weekly, September 1st, 1997

Patients who undergo a certain type of coronary angioplasty can reduce their risk of death, heart attack, or the need to re-open cardiac vessels for up to three years by receiving an expensive anticlotting antibody known as abciximab.

Eric J. Topol, M.D., from the Cleveland Clinic Foundation, Ohio, and colleagues found a 19 percent reduction in the risk of death, heart attack, and need to re-open the arteries after the first year with use of abciximab when compared with placebo. At three years, there was a 13 percent reduction.

Their study was published in the August 13, 1997 issue of The Journal of the American Medical Association.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-09-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry